Ann: Imugene Receives A$20 million for Convertible Notes Issuance, page-186

Where from here?

No rocket scientist needed to predict any sp if any update is considered to be negative - All over Red Rover.

What if positive?

Looking at the daily trading volume over the past weeks it looks like the big guys either have left or are " dormant". The friendly buy / sell - BOT is still active, but that's it. No 5-10m shares line wipes in either direction for a while, IMU "becoming inactive".

That would suggest that, if most big guys have left, any re-entry by them could drive the sp significantly up and as the big guys will have to re-establish their sp-controlling holdings and any sell down should be minimal. But if these guys are just "dormant" then any sp rise would be limited unless the anns is sooooooo compelling that new forces would enter and counter any dumping efforts.

And that leaves any holder with the question: Can such a mind-blowing anns be expected?

IMU was the only comp interested in Azer-Cel in 2023 despite the ph1 data were available to everyone. Unless ph1b is significantly exceeding those it will be unlikely any big pockets will look at IMU - a big task for IMU.

CF33: The platform applications atm revolve around the 2 patients with bile duct cancer. If the planned extension trial doesn't deliver similar results then CF33 will be in question whether those 2 patients actually had their cancer gone / reduced by CF33.

Her-Vaxx is on the market since 2021 and neither the Gurus such as Shah and Eckstein nor Hopper were able to sell it, why expecting it now? PD1-Vaxx will enter a ph2 trial mid 2025, 1 1/2 years after the initial anns in December '23 - no immediate data to be expected from that side.


A lot has to go IMU's way and not one tiny bit is allowed to go wrong.

Everyone has to work out the odds for success for themselves but I don't think those are high.